MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	gefitinib + tepotinib Sensitive: C3 – Early Trials gefitinib + tepotinib Sensitive : C3	gefitinib + tepotinib Sensitive: C3 – Early Trials gefitinib + tepotinib Sensitive : C3
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	gefitinib + capmatinib Sensitive: C3 – Early Trials gefitinib + capmatinib Sensitive : C3	gefitinib + capmatinib Sensitive: C3 – Early Trials gefitinib + capmatinib Sensitive : C3
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C3 – Early Trials osimertinib + savolitinib Sensitive : C3	osimertinib + savolitinib Sensitive: C3 – Early Trials osimertinib + savolitinib Sensitive : C3
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	osimertinib + tepotinib Sensitive: C3 – Early Trials osimertinib + tepotinib Sensitive : C3	osimertinib + tepotinib Sensitive: C3 – Early Trials osimertinib + tepotinib Sensitive : C3
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	osimertinib + capmatinib Sensitive: C3 – Early Trials osimertinib + capmatinib Sensitive : C3	osimertinib + capmatinib Sensitive: C3 – Early Trials osimertinib + capmatinib Sensitive : C3
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	osimertinib Resistant: D – Preclinical osimertinib Resistant : D	osimertinib Resistant: D – Preclinical osimertinib Resistant : D
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	lazertinib + ABN401 Sensitive: D – Preclinical lazertinib + ABN401 Sensitive : D	lazertinib + ABN401 Sensitive: D – Preclinical lazertinib + ABN401 Sensitive : D

MET amplification + EGFR mutation

Associations